Latest news with #AlmacGroup
Irish Post
28-05-2025
- Business
- Irish Post
Co. Armagh pharmaceutical company Almac Group announces annual sales of more than £1bn
A PHARMACEUTICAL firm based in Co. Armagh has announced that annual sales have exceeded £1bn for the first time. Almac Group, which has its global headquarters in Craigavon, reported revenues of £1.027bn for the year to September 2024, marking a 7 per cent (£69.5m) increase on the previous year. Pre-tax profits also rose by 27 per cent to £119m, up from £93.8m the previous year "Today's results mark another successful year of growth for Almac," said chairman and chief executive Alan Armstrong. Almac Group was founded in 2002 by Co. Tyrone native Allen McClay. He had previously founded the Galen pharmaceutical company in Craigavon in 1968 — which subsequently became Northern Ireland's first £1bn company — before leaving the firm in 2001. After McClay established Almac with the purchase of several Galen businesses, the group acquired pharmaceutical manufacturing operations from Galen in 2003 before purchasing the firm in 2004. Today, Almac is at the forefront of developing, manufacturing, testing and distributing essential medicines to patients around the world. 'Innovate and expand' During this financial year, the group was involved in the development of hundreds of life-saving drugs spanning more than 20 therapeutic areas including oncology, cardiology, immunology, gene therapy and neurology. The company's latest figures cover the third year of the group's £400m global expansion plans, which were announced in November 2021. As part of the plans, the group opened a new state-of-the-art, £65m commercial manufacturing facility at Craigavon in March of this year. The 100,000sq ft facility enhances existing capabilities in commercial manufacture of oral dose treatments for a variety of therapeutic areas. As well as its global headquarters in Craigavon, Almac Group — which employs more than 7,700 people at 18 facilities across the globe — also has its European headquarters in Dundalk. The company's US and Asia Pacific headquarters are in Pennsylvania and Singapore respectively, while it has dozens of sites across Europe, Asia, North and South America as well as Africa and Australia. "As a privately-owned and independent company, we re-invest all our profits back into the business, enabling us to innovate and expand to meet the growing needs of our global clients, working in partnership to advance human health," added Mr Armstrong. "I am proud of the continued progress we are making, which is thanks to the dedication of our valued global workforce." See More: Almac Group, Armagh, Tyrone
Belfast Telegraph
28-05-2025
- Business
- Belfast Telegraph
NI pharma firm passes £1bn sales milestone for first time
The milestone means it's joined the elite of successful homegrown firms with over £1bn sales including Pilgrim's Europe – which has now hit the £2bn mark – and Henderson Group. Figures released today (Wed) for Almac's financial year ending September 30 2024 reveal £1.027bn of revenues, a £69.5m (7%) increase from 2023. Pre-tax profits rose by 27% to £119m, up from £93.8m in the previous year, and average employee numbers grew by 3% to over 7,700 over the same period. Almac Group, which carries out pharmaceutical development and manufacturing around the globe, said the figures were its highest ever revenue, profit and employee numbers. Almac said it reinvests all its profits back into the business, and had now completed the fourth year of a £400m+ global capital investment programme, first announced in November 2021. The programme has included a centre of excellence for diagnostic development and commercial manufacturing, a 100,000 sq ft pharmaceutical manufacturing facility, and an expansion of cryogenic and ultra-low temperature service capabilities for clinical supply across Durham, North Carolina and Singapore. And it said a major expansion continues to clinical production and distribution capabilities in Souderton, Pennsylvania. Almac said its work placed it 'at the forefront of developing, manufacturing, testing and distributing essential medicines to patients around the world'. Over the financial year, the group had been involved in developing hundreds of life-saving drugs across more than 30 areas like oncology, cardiology, immunology, gene therapy and neurology. Alan Armstrong, Almac Group chairman and CEO said: 'Today's results mark another successful year of growth for Almac. "As a privately-owned and independent company, we re-invest all our profits back into the business, enabling us to innovate and expand to meet the growing needs of our global clients, working in partnership to advance human health. 'I am proud of the continued progress we are making, which is thanks to the dedication of our valued global workforce.' Mr Armstrong received the Lifetime Achievement Awards at the 2025 Belfast Telegraph Business Awards earlier this month. The judging panel said: 'His principles are second to none and he has grown Almac to such a significant global company – but stayed true to the legacy left by founder Sir Allen McClay.' On receiving the award, Mr Armstrong said: 'At Almac, our mission is advancing human health. It's fulfilling to be part of developing products and compounds that will ultimately help humanity.' Sir Allen founded Almac Group in 2002, 34 years after he had established his firm pharmaceutical company, Galen. Trump agrees to delay 50% tariffs on EU imports until July 9 He built Galen up to become Northern Ireland's first £1bn business, and led a successful float of the company on the stock market. Sir Allen resigned from Galen at that point, setting up Almac in his late sixties. Pilgrim's Europe, formerly Moy Park, became the first homegrown company in Northern Ireland to achieve £2bn in sales in 2023. Henderson Group, which owns the Spar and Eurospar convenience retail franchises here, recorded sales of £1.3bn in 2023. And over the year to July 2024, W&R Barnett, which trades in goods such as as molasses, animal feed and corrugated board, reported turnover of £1.6bn.
Belfast Telegraph
01-05-2025
- Business
- Belfast Telegraph
Belfast Telegraph Business Awards 2025: Find out who wins on a night of celebration
live | The Belfast Telegraph Business Awards, in partnership with Ulster Bank, are celebrating their 25th anniversary It's an historic night as the Belfast Telegraph Business Awards, in partnership with Ulster Bank, are celebrating their 25th anniversary. Companies from a range of sectors have been shortlisted across 17 categories and are gathering tonight at the Crowne Plaza for a celebration of the best across Northern Ireland business. Find out who wins as we bring you live coverage from the evening: Today 11:12 AM This year's shortlists Companies from a range of sectors have been shortlisted across 17 categories, from Best Emerging Business to Outstanding Company of the Year. All are eagerly waiting to find out who will take home the awards this evening. Shortlists for Belfast Telegraph Business Awards partnered with Ulster Bank The shortlist for the 2025 Belfast Telegraph Business Awards in partnership with Ulster Bank is revealed today. Today 11:11 AM What happened at last year's awards? Belfast Telegraph Business Awards 2024: Major NI company named Outstanding Business of the Year Almac Group has been named Outstanding Business of the Year while Dame Rotha Johnston received a Lifetime Achievement Award at the 2024 Belfast Telegraph Business Awards in partnership with Ulster Bank. Today 11:09 AM Welcome to the 2025 Belfast Telegraph Business Awards Members of Northern Ireland's business community are gathering in Belfast's Crowne Plaza Hotel this evening for the 2025 Belfast Telegraph Business Awards. Now in their 25th year, the awards showcase the very best of business and innovation in Northern Ireland and the event is due to attract nearly 500 guests. Speaking ahead of the event Clare Guinness, chief executive of Belfast Chamber and chair of the judging panel, said the awards 'give companies across NI a chance to be recognised for their contribution to our economy and society'. 'Year on year the judging panel is blown away by the initiatives and performance of our business community and we look forward to celebrating with the finalists and winners.'
Yahoo
31-01-2025
- Business
- Yahoo
DNases, Ligases, and RNA Polymerases Market Research 2024-2034: Burgeoning Opportunities in Emerging Applications, Collaborative Partnerships, and Adoption of Enzyme-based Diagnostics
Global DNases, Ligases, And RNA Polymerases Market Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "Dnases, Ligases, and RNA Polymerases Market by Dnases Application, by Ligases Application, by RNA Polymerases Application, by End-user, and by Region" report has been added to global DNases, ligases, and RNA polymerases market accounted for USD 0.804 billion in 2023 and is expected to reach USD 2.45 billion by 2034 with a CAGR of 10.66% during the forecast period 2024-2034. The market will grow due to factors such as growing emphasis on life sciences research, advancements in RNA-based therapeutics, rising demand for biopharmaceutical products, and support from institutions and the government. The market for ligases, RNA polymerases, and DNases worldwide is driven by several reasons. These enzymes are needed for the growing biopharmaceutical industry to produce biocatalysts, purify DNA, and possibly even use gene therapy. RNA polymerases are necessary to manufacture mRNA vaccines and RNAi therapeutics, opening up a new market for growth. For instance, Almac Group said in March 2024 that the two newly constructed facilities at its headquarters in Craigavon, Northern Ireland, were complete. The peptide API synthesis as well as the commercial manufacturing and packing of sachet pharma product presentations are anticipated to increase with the opening of these new facilities. North American region is anticipated to have the highest revenue share during the forecast period owing to advanced healthcare infrastructure, significant investments in research and development, and a high adoption rate of molecular biology technologies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding biotechnology and pharmaceutical industries, increasing government initiatives to support scientific research, and rising investment in healthcare infrastructure. For instance, the NEBNext UltraExpress DNA and RNA library preparation kits for next-generation sequencing were introduced by New England Biolabs in November DNases application, the biopharmaceutical processing segment accounted for the highest revenue-grossing segment in the global DNases, ligases, and RNA polymerases market in 2023 owing to the increasing demand for biopharmaceuticals, extensive use in removing DNA contaminants, and significant investments in research and development. For instance, in January 2024, the company's selectAZyme enzyme screening collection was expanded with the introduction of an RNA Ligase (RNAL) enzyme kit by Almac Science, a part of Almac Group. Additionally, the other applications segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding use of these enzymes in emerging fields such as synthetic biology, personalized medicine, and advanced molecular ligases application, the other applications segment accounted for the highest revenue-grossing segment in the global DNases, ligases, and RNA polymerases market in 2023 owing to the increasing utilization in diverse fields such as gene therapy, molecular diagnostics, and synthetic biology, as well as significant advancements in biotechnological research. For instance, in March 2023, the University of Manchester, AstraZeneca, Novartis, and the Centre for Process Innovation Limited joined together to transform oligonucleotide synthesis. Additionally, the oligonucleotide synthesis segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for custom oligonucleotides in genetic research, advancements in gene editing technologies like CRISPR, and increasing applications in diagnostics and therapeuticsBy RNA polymerases application, the mRNA production segment accounted for the highest revenue-grossing segment in the global DNases, ligases, and RNA polymerases market in 2023 owing to the surge in demand for mRNA vaccines, especially COVID-19 vaccines, and the increasing development of mRNA-based therapeutics for various diseases. For instance, in January 2024, Almac Science, a division of the Almac Group, added an RNA Ligase (RNAL) enzyme kit to the company's selectAZyme enzyme screening library. Additionally, the others segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing application of these enzymes in innovative fields such as synthetic biology, personalized medicine, and advanced molecular diagnostics, as well as ongoing technological advancements and expanding research end-user, the research and academic institutions segment accounted for the highest revenue-grossing segment in the global DNases, ligases, and RNA polymerases market in 2023 owing to the significant demand for advanced molecular biology tools and techniques for various research projects and academic studies. For instance, Illumina and Deerfield Management worked together in May 2022. The companies collaborated to select projects that had a higher chance of success utilizing genetic methods and intrinsic knowledge in order to reduce the expense of research and development and encourage the approval of innovative treatments. Additionally, the diagnostic laboratories segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of infectious diseases and the rising demand for accurate molecular diagnostics for early disease detection and management. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2023 - 2034 Estimated Market Value (USD) in 2023 $0.8 Billion Forecasted Market Value (USD) by 2034 $2.45 Billion Compound Annual Growth Rate 10.6% Regions Covered Global Market Dynamics Drivers Analysis Increasing research activities Advancements in biotechnology Rising demand for personalized medicine Expansion of the biopharmaceutical industry Restraints Analysis Regulatory hurdles High cost Technical challenges Opportunities Analysis Emerging applications Collaborative partnerships Adoption of enzyme-based diagnostics Threats Analysis Competition from alternative technologies Intellectual property issues Safety concerns Trend Analysis CRISPR-Cas technologies Sustainability initiatives Industrial biocatalysis Competitor Analysis Thermo Fisher Scientific Inc. New England Biolabs Merck KGaA Promega Corporation Agilent Technologies QIAGEN Takara Bio Inc. Illumina Inc. Roche Holding AG Bio-Rad Laboratories Inc. Enzymatics Inc. GenScript Biotech Corporation Lonza Group Ltd. OriGene Technologies Inc. Becton Dickinson and Company (BD) DNases, Ligases, And RNA Polymerases Market Analysis & Forecast by DNases Application 2023 - 2034 (Revenue USD Bn) Biopharmaceutical Processing Other Applications DNases, Ligases, And RNA Polymerases Market Analysis & Forecast by Ligases Application 2023 - 2034 (Revenue USD Bn) Oligonucleotide Synthesis Other Applications DNases, Ligases, And RNA Polymerases Market Analysis & Forecast by RNA Polymerases Application 2023 - 2034 (Revenue USD Bn) mRNA Production Other Applications DNases, Ligases, And RNA Polymerases Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn) Biopharmaceutical Processing Research and Academic Institutions Diagnostic Laboratories Pharmaceutical Companies DNases, Ligases, And RNA Polymerases Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn) North America U.S. Canada Europe Germany France UK Spain Italy Rest of Europe Asia Pacific China Japan India Australia South Korea Rest of APAC Latin America Brazil Mexico Argentina Rest of LATAM Middle East & Africa South Africa GCC Rest of MEA For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Global DNases, Ligases, And RNA Polymerases Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
